China — Revenue
Geographic · RevenueEli Lilly China — Revenue decreased by 15.4% to $473.90M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 10.4%, from $429.20M to $473.90M. Over 4 years (FY 2021 to FY 2025), China — Revenue shows an upward trend with a 4.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful product launches, expanded market access, or growing demand for the company's core therapeutic offerings in China. A decrease may signal increased local competition, pricing pressures from government procurement policies, or supply chain challenges.
Detailed definition
This metric represents the total net sales generated from pharmaceutical products sold within the China geographic regio...
Peer comparison
Comparable to regional revenue reporting for other multinational pharmaceutical firms, though specific exposure levels vary significantly based on the company's historical footprint in the Chinese market.
lly_segment_cn_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $522.50M | $400.30M | $376.40M | $406.50M | $352.10M | $343.40M | $350.80M | $372.70M | $399.00M | $390.80M | $377.20M | $376.20M | $395.10M | $459.90M | $429.20M | $450.80M | $465.90M | $560.40M | $473.90M |
| QoQ Change | — | -23.4% | -6.0% | +8.0% | -13.4% | -2.5% | +2.2% | +6.2% | +7.1% | -2.1% | -3.5% | -0.3% | +5.0% | +16.4% | -6.7% | +5.0% | +3.3% | +20.3% | -15.4% |
| YoY Change | — | — | — | — | -32.6% | -14.2% | -6.8% | -8.3% | +13.3% | +13.8% | +7.5% | +0.9% | -1.0% | +17.7% | +13.8% | +19.8% | +17.9% | +21.9% | +10.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's china — revenue?
- Eli Lilly (LLY) reported china — revenue of $473.90M in Q4 2025.
- How has Eli Lilly's china — revenue changed year-over-year?
- Eli Lilly's china — revenue increased by 10.4% year-over-year, from $429.20M to $473.90M.
- What is the long-term trend for Eli Lilly's china — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's china — revenue has grown at a 4.1% compound annual growth rate (CAGR), from $1.66B to $1.95B.
- What does china — revenue mean?
- The total revenue generated from sales of pharmaceutical products in China.